NCT04578158

Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19

A Prospective, Randomized, Open-labelled, Controlled Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With Diagnosis of COVID-19.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 152 (actual)
• Sponsor: Liaquat University of Medical & Health Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate if Quercetin Phytosome is beneficial for the treatment of COVID-19.

Detailed description

This is a randomized, open-labelled and controlled study aimed to investigate the adjuvant benefits of Quercetin Phytosome in community-based subjects with confirmed SARS-CoV-2 infection (by RT-PCR). The study has two arms. In one arm the subjects will receive standard COVID-19 care as per the hospital/physician guidelines, whereas in the other arm the subjects will receive standard COVID-19 care + Quercetin Phytosome. The treatment will continue for 30 days. It is proposed that Quercetin Phytosome will contribute to boosting the natural immunity of the subjects and will help in preventing the COVID-19 disease progression i.e preventing the need of hospitalisation.

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	Standard COVID-19 care	Patients will receive standard covid-19 care as per the hospital/physician guidelines
DIETARY_SUPPLEMENT	Quercetin Phytosome	Patients will receive a daily dose of 400 mg of oral Quercetin Phytosome

Timeline

• Start date: 2020-09-29
• Primary completion: 2021-03-28
• Completion: 2021-04-15
• First posted: 2020-10-08
• Last updated: 2021-04-22

Locations

1 site across 1 country: Pakistan